A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer.

Ugur Sahin,Martin Schuler,Heike Richly,Stefan Bauer,Anna Krilova,Tobias Dechow,Markus Jerling,Magdalena Utsch,Christoph Rohde,Karl Dhaene,Christoph Huber,Özlem Türeci

European Journal of Cancer（2018）

引用 67|浏览12

暂无评分

摘要

•CLDN18.2 is a tumour-specific marker in gastric or gastro-oesophageal junction cancers.•IMAB362, an anti-CLDN18.2 mAb, mediates tumour cell death through ADCC and CDC.•Single-dose IMAB362 at doses of 33–1000 mg/m2 was generally well tolerated.•IMAB362 (300–600 mg/m2) was determined as suitable for further evaluation.

查看译文

关键词

Immunotherapy,Gastric cancer,Gastro-oesophageal junction,Phase I clinical trials,Biomarkers

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要